1. Home
  2. WOK vs ATNM Comparison

WOK vs ATNM Comparison

Compare WOK & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WOK
  • ATNM
  • Stock Information
  • Founded
  • WOK 2002
  • ATNM 2000
  • Country
  • WOK China
  • ATNM United States
  • Employees
  • WOK N/A
  • ATNM N/A
  • Industry
  • WOK
  • ATNM Biotechnology: Pharmaceutical Preparations
  • Sector
  • WOK
  • ATNM Health Care
  • Exchange
  • WOK NYSE
  • ATNM Nasdaq
  • Market Cap
  • WOK 70.3M
  • ATNM 56.5M
  • IPO Year
  • WOK 2024
  • ATNM N/A
  • Fundamental
  • Price
  • WOK $5.01
  • ATNM $1.40
  • Analyst Decision
  • WOK
  • ATNM Strong Buy
  • Analyst Count
  • WOK 0
  • ATNM 4
  • Target Price
  • WOK N/A
  • ATNM $8.75
  • AVG Volume (30 Days)
  • WOK 221.3K
  • ATNM 342.1K
  • Earning Date
  • WOK 02-03-2025
  • ATNM 11-14-2024
  • Dividend Yield
  • WOK N/A
  • ATNM N/A
  • EPS Growth
  • WOK N/A
  • ATNM N/A
  • EPS
  • WOK N/A
  • ATNM N/A
  • Revenue
  • WOK $9,863,642.00
  • ATNM $81,000.00
  • Revenue This Year
  • WOK N/A
  • ATNM $138.42
  • Revenue Next Year
  • WOK N/A
  • ATNM $19,479.88
  • P/E Ratio
  • WOK N/A
  • ATNM N/A
  • Revenue Growth
  • WOK N/A
  • ATNM N/A
  • 52 Week Low
  • WOK $3.26
  • ATNM $1.10
  • 52 Week High
  • WOK $8.45
  • ATNM $10.24
  • Technical
  • Relative Strength Index (RSI)
  • WOK N/A
  • ATNM 56.03
  • Support Level
  • WOK N/A
  • ATNM $1.18
  • Resistance Level
  • WOK N/A
  • ATNM $1.48
  • Average True Range (ATR)
  • WOK 0.00
  • ATNM 0.10
  • MACD
  • WOK 0.00
  • ATNM 0.01
  • Stochastic Oscillator
  • WOK 0.00
  • ATNM 75.00

About WOK WORK MEDICAL TECHNOLOGY GROUP LTD

WORK Medical Technology Group Ltd is a manufacturer of medical devices, and it is committed to providing professional and reliable medical devices to the world.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: